WT1 and leukemia: Nevertheless, several TCR constructs derived from conventional, human T-cells with physiologic avidities have undergone extensive preclinical testing and will now be studied in human leukemia trials including those that redirect T-cells against HLA-A2 restricted epitopes of HA-1 and WT-1[100, 108].